U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

The Trump administration is moving forward with the defense of a Biden-era plan that allows Medicare to negotiate drug prices against Novartis AG’s appeal at the Third Circuit.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...